14 unknown, 3 completed, 3 not yet recruiting, 2 active not recruiting. 25 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Unknown 14, Completed 3, Not yet recruiting 3, Active not recruiting 2, Recruiting 2, Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Anlotinib: new trials by email Literature Review of Anlotinib trials Research Report on Anlotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy Benmelstobart, SBRT, Anlotinib - Hepatocellular Carcinoma (HCC), First-line Targeted Therapy Failure | Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 29 | 2026-04-20 | 2026-04-17 |
| Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study neoadjuvant therapy, Surgery, Adjuvant therapy - NSCLC, Tislelizumab | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 34 | 2025-07-25 | 2026-10-13 |
| Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC Benmelstobart, Anlotinib, Cisplatin - Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 45 | 2024-12-03 | 2024-11-21 |
| Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer Anlotinib+Capeox, Capeox - Neoadjuvant Treatment, Rectal Cancer | Phase 2 | Withdrawn | Shanghai Minimally Invasive Surgery Center | 2023-11-01 | 2021-09-28 | |
| Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation Aumolertinib,Anlotinib - Aumolertinib, Anlotinib | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 47 | 2023-03-31 | 2023-03-21 |
| Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma Anlotinib, Radiotherapy, Surgery - Soft Tissue Sarcoma, High Risk of Recurrence | Phase 2 | Unknown | Ruijin Hospital | 41 | 2022-11-01 | 2022-11-02 |
| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Niraparib plus anlotinib - Ovarian Carcinoma, Survival Outcomes | Phase 2 | Unknown | Lei Li | 36 | 2022-03-27 | 2022-04-13 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma Anlotinib, Cisplatin, Carboplatin - Urothelial Carcinoma, Anlotinib | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2021-10-01 | 2021-09-01 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Drug: Anlotinib, Drug: Carboplatin/Paclitaxel - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Active not recruiting | Wenjun Cheng | 56 | 2021-08-24 | 2024-07-03 |
| Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer Anlotinib plus AK105 - Anlotinib, Anti-PD-1 Antibody | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 29 | 2021-05-12 | 2023-06-22 |
| Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC Neoadjuvant therapy 1 - Sintilimab, Lung Cancer | Phase 2 | Active not recruiting | Tang-Du Hospital | 45 | 2021-03-01 | 2024-10-18 |
| SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer SHR-1210 plus Anlotinib - SHR-1210, Anlotinib | Phase 2 | Unknown | Peking Union Medical College Hospital | 33 | 2021-03-01 | 2021-03-15 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Anlotinib, Olaparib - Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Neoplasms | Phase 2 | Unknown | Xiaoxiang Chen | 68 | 2020-10-28 | 2020-10-30 |
| Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) Anlotinib plus Sintilimab - Colorectal Cancer, Immunotherapy | Phase 2 | Completed | Shanghai Changzheng Hospital | 30 | 2020-06-01 | 2024-04-23 |
| Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01） Anlotinib hydrochloride - Sarcoma,Soft Tissue, Extremity | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2020-05-01 | 2026-06-04 |
| Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence Anlotinib Hydrochloride, TACE - Hepatocellular Carcinoma, TACE | Phase 2 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 30 | 2020-04-23 | 2023-01-17 |
| Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study Anlotinib In Combination With Durvalumab - Anlotinib, Durvalumab | Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 33 | 2020-04-01 | 2020-03-19 |
| Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study Anlotinib In Combination With PD-1/L1 Inhibitor - NSCLC, Anlotinib | Phase 2 | Unknown | Xiaorong Dong | 33 | 2020-04-01 | 2020-03-18 |
| Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) Anlotinib Plus Toripalimab - Gastric Cancer, Immunotherapy | Phase 2 | Unknown | Shanghai Changzheng Hospital | 24 | 2020-02-10 | 2024-07-10 |
| A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer anlotinib hydrochloride combined with irinotecan or docetaxel - Relapsed Small Cell Lung Cancer, Anlotinib | Phase 2 | Unknown | First People's Hospital of Hangzhou | 40 | 2019-12-30 | 2021-02-17 |
Showing 20 of 25. Sign in to see all of them.
Ovarian Neoplasms (3) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Ovarian Epithelial (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Lung Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Ovarian Diseases (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Urogenital Neoplasms (2) · Adnexal Diseases (1)
Neoplasms (16) · Neoplasms by Site (13) · Neoplasms by Histologic Type (6) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Lung Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4) · Urogenital Diseases (4) · Endocrine Gland Neoplasms (3)
anlotinib (20) · sintilimab (3) · Carboplatin (2) · Cisplatin (2) · Drug Therapy (2) · Surgical Procedures, Operative (2) · CP protocol (1) · Chemotherapy, Adjuvant (1) · Docetaxel (1) · Etoposide (1) · Gemcitabine (1) · Irinotecan (1) · Neoadjuvant Therapy (1) · Paclitaxel (1) · Radiotherapy (1)
Peking Union Medical College Hospital (2) · Shanghai Changzheng Hospital (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · First People's Hospital of Hangzhou (1) · Lei Li (1) · Nanfang Hospital, Southern Medical University (1) · Peng Yuan (1) · Qilu Hospital of Shandong University (1) · Ruijin Hospital (1) · Shanghai Chest Hospital (1) · Shanghai Minimally Invasive Surgery Center (1) · Sun Yat-sen University (1) · Tang-Du Hospital (1)
China (20)
Baohui Han (1) · Chen Jinzhang (1) · Lei Li, M.D. (1) · Peng Yuan (1) · Wenjun Cheng, MD,PhD (1) · Xiaoxiang Chen, MD,PhD (1) · Yuanjie Niu, MD,PhD (1) · Yuhui Shen, MD (1) · Zheng Wu, PhD (1) · Zhiming Li (1)
PMID 35623069, PMID 36116169, PMID 36749752, PMID 39465257, PMID 40555062, PMID 40954146, PMID 41484570